Literature DB >> 32133113

Rational investigations in irritable bowel syndrome.

Christopher J Black1, Alexander C Ford1.   

Abstract

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder which accounts for a substantial proportion of a gastroenterologist's time in the outpatient clinic. However, there is variability in approaches to diagnosis and investigation between physicians, dependent on expertise. Many patients express disappointment over the lack of a patient-centred approach. Consequently, there have been calls for the care of patients with IBS to be standardised, a process which aims to promote high-quality and high-value care. Making an early diagnosis, based on a clinical assessment of symptoms, while limiting use of investigations, are key tenets of this process. Exhaustive investigation to exclude all organic pathology is unnecessary, and may be counterproductive. Routine blood tests in suspected IBS have low yield, but are an acceptable part of routine practice. All patients should have coeliac serology tested, regardless of their predominant stool form. Patients with diarrhoea should have a faecal calprotectin measured, and should proceed to colonoscopy to exclude inflammatory bowel disease (IBD) if this is positive. Beyond this, the need for investigations should be made on a case-by-case basis, contingent on the reporting of known risk factors for organic pathology. Colonoscopy should be considered in any patient with alarm features for colorectal cancer, and in those whose clinical features are suggestive of microscopic colitis. A 23-seleno-25-homotaurocholic acid (SeHCAT) scan should be considered in patients with IBS-D, a third of whom may actually have bile acid diarrhoea. There is no role for routine hydrogen breath tests for lactose malabsorption or small intestinal bacterial overgrowth. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  irritable bowel syndrome

Year:  2019        PMID: 32133113      PMCID: PMC7043084          DOI: 10.1136/flgastro-2019-101211

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN: 2041-4137


  67 in total

1.  Predictors of conventional and alternative health care seeking for irritable bowel syndrome and functional dyspepsia.

Authors:  N A Koloski; N J Talley; S S Huskic; P M Boyce
Journal:  Aliment Pharmacol Ther       Date:  2003-03-15       Impact factor: 8.171

2.  Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care.

Authors:  Alexander C Ford; Premysl Bercik; David G Morgan; Carolina Bolino; Maria Ines Pintos-Sanchez; Paul Moayyedi
Journal:  Gastroenterology       Date:  2013-08-28       Impact factor: 22.682

3.  Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis.

Authors:  Rebecca M Lovell; Alexander C Ford
Journal:  Clin Gastroenterol Hepatol       Date:  2012-03-15       Impact factor: 11.382

4.  Utility of red flag symptom exclusions in the diagnosis of irritable bowel syndrome.

Authors:  W E Whitehead; O S Palsson; A D Feld; R L Levy; M VON Korff; M J Turner; D A Drossman
Journal:  Aliment Pharmacol Ther       Date:  2006-07-01       Impact factor: 8.171

5.  Prevalence of functional gastrointestinal disorders among consecutive new patient referrals to a gastroenterology clinic.

Authors:  Uday N Shivaji; Alexander C Ford
Journal:  Frontline Gastroenterol       Date:  2014-01-21

6.  Prevalence of organic colonic lesions in patients meeting Rome III criteria for diagnosis of IBS: a prospective multi-center study utilizing colonoscopy.

Authors:  Shunji Ishihara; Kazuo Yashima; Yoshinori Kushiyama; Akio Izumi; Kousaku Kawashima; Hirofumi Fujishiro; Haruhiko Kojo; Yoshinori Komazawa; Tetsuro Hamamoto; Tetsuo Yamamoto; Yuichiro Sasaki; Tatsunori Shimizu; Eiji Okamoto; Teiji Yoshimura; Koichiro Furuta; Naoya Noguchi; Hisao Tanaka; Yoshikazu Murawaki; Yoshikazu Kinoshita
Journal:  J Gastroenterol       Date:  2012-03-30       Impact factor: 7.527

7.  Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care.

Authors:  D S Sanders; M J Carter; D P Hurlstone; A Pearce; A M Ward; M E McAlindon; A J Lobo
Journal:  Lancet       Date:  2001-11-03       Impact factor: 79.321

8.  Epidemiology and health care seeking in the functional GI disorders: a population-based study.

Authors:  Natasha A Koloski; Nicholas J Talley; Philip M Boyce
Journal:  Am J Gastroenterol       Date:  2002-09       Impact factor: 10.864

9.  Using best practice to create a pathway to improve management of irritable bowel syndrome: aiming for timely diagnosis, effective treatment and equitable care.

Authors:  Marianne Williams; Yvonne Barclay; Rosie Benneyworth; Steve Gore; Zoe Hamilton; Rudi Matull; Iain Phillips; Leah Seamark; Kate Staveley; Steve Thole; Emma Greig
Journal:  Frontline Gastroenterol       Date:  2016-08-01

Review 10.  Review article: the economic impact of the irritable bowel syndrome.

Authors:  C Canavan; J West; T Card
Journal:  Aliment Pharmacol Ther       Date:  2014-09-09       Impact factor: 8.171

View more
  4 in total

1.  Do Socio-Demographics Play a Role in the Prevalence of Red Flags and Pursuant Colonoscopies in Patients With Irritable Bowel Syndrome?

Authors:  Anmol Mittal; Shivani Gupta; Faiz Afridi; Anthony Dimitrey; Sushil Ahlawat
Journal:  Cureus       Date:  2022-05-19

Review 2.  Global burden of irritable bowel syndrome: trends, predictions and risk factors.

Authors:  Christopher J Black; Alexander C Ford
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-04-15       Impact factor: 46.802

Review 3.  Best management of irritable bowel syndrome.

Authors:  Christopher J Black; Alexander Charles Ford
Journal:  Frontline Gastroenterol       Date:  2020-05-28

4.  Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom.

Authors:  Vivek C Goodoory; Cho Ee Ng; Christopher J Black; Alexander C Ford
Journal:  Aliment Pharmacol Ther       Date:  2022-05-01       Impact factor: 9.524

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.